Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of dazucorilant in amyotrophic lateral sclerosis
NL-OMON60789Phase 2Recruiting
- Sponsor
- Corcept Therapeutics
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dazucorilant in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Corcept Therapeutics. Primary endpoints: Change from baseline to Week 24 in ALS Functional Rating Scale-Revised total score, Incidence of adverse events and serious adverse events and 2 more. Started Nov 2022; status: recruiting.
02
Drugs
dazucorilant
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON60789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60789.